Results of preliminary correlative analysis from the PLAT-08 study show rapamycin-regulated in vivo expansion and activation of SC-DARIC33 T cells as well as concurrent anti-CD33 activity Enhanced anti-acute myeloid leukemia (AML) potency was obtained with the combination of regulated IL-15
bbT369, a dual-targeted (CD79a/CD20) and CBLB gene edited autologous CAR T for non-Hodgkin lymphoma, showed edit-driven enhanced T cell activity in multiple preclinical models RESET, a novel TCR coupled antigen receptor architecture, displayed markedly increased targeting sensitivity and
Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma (RRMM) from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from KarMMa-3 study of health-related quality of life in patients who received Abecma will be presented at
Abecma (idecabtagene vicleucel) generated $118 million U.S. commercial revenue in 1Q 2023, supporting upper end of U.S. revenue guidance of $470-570 million U.S. FDA accepted supplemental Biologics License Application (sBLA) based on results from the pivotal phase 3 KarMMa-3 study of Abecma;
Late-breaking oral presentation will show early findings from Phase I PLAT-08 study of SC-DARIC33, an investigational, potentially first-in-class CD33-targeting CAR T in pediatric and young adults with relapsed/refractory acute myeloid leukemia (AML) Updates on the Company’s portfolio include
2seventy bio plans to present data at virtual Research and Development deep dive on May 19, 2023 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 1, 2023-- 2seventy bio, Inc. (Nasdaq: TSVT) a leading immuno-oncology cell therapy company, today announced that it has achieved a preclinical $15 million
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 28, 2023-- 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, will announce its first quarter 2023 financial results on Wednesday, May 3, 2023 . 2seventy bio will host a conference call and webcast at 4:30 p.m.
U.S. FDA accepted Bristol Myers Squibb and 2seventy bio’s supplemental Biologics License Application and has assigned a target action date of December 16, 2023 European Medicines Agency has validated Bristol Myers Squibb’s Type II variation application for Abecma Bristol Myers Squibb’s supplemental
Abecma (idecabtagene vicleucel) generated $ 94M U.S. commercial revenue in 4Q 2022, $297M in FY 2022; anticipate $470-$570M U.S. revenue in 2023 Positive data from Phase 3 KarMMa-3 study published in New England Journal of Medicine Ended 2022 with $268M cash, cash equivalents, and marketable
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 8, 2023-- 2seventy bio, Inc. (Nasdaq: TSVT) today announced the appointment of Wei Lin , M.D. to the company’s Board of Directors, effective immediately. “We are thrilled to welcome Dr. Wei Lin to 2seventy’s Board during an exciting time in our Company’s
